Sponsor or institution

Clinical trials and research at Tianjin Medical University Second Hospital

• 22Clinical trials
• 2New in 30 days
• 1Country

Newest trials

All recruiting trials (22)

• AI-assisted whole-course management for safe medicine use in advanced solid tumors

  A real-world study compares a smartphone-based digital management system with usual care to see if it reduces drug-related problems and healthcare needs for adults with advanced solid tumors receiving cancer therapy.

  Recruiting at 2 sites Tianjin Medical University Second Hospital · Tianjin, Tianjin Municipality and 1 other locations · NCT07917351

• Organoid Drug Sensitivity-Guided Therapy for Refractory Tumors

  This study tests whether tumor organoids created from a patient’s tissue can help doctors pick drugs for adults with hard‑to-treat, unresectable, or metastatic cancers after standard options have been exhausted.

  Recruiting Tianjin Medical University Second Hospital · Tianjin, Tianjin Municipality · NCT07906301

• Active surveillance versus single-dose intravesical chemo after TURBT in low-shedding intermediate-risk NMIBC

  This study tests whether some patients with intermediate-risk non-muscle-invasive bladder cancer can skip additional bladder chemotherapy after complete tumor removal if urine tests show a low-shedding profile.

  Recruiting at 5 sites Tianjin Medical University Second Hospital · Daqing and 4 other locations · NCT07749924

• Becotatug Vedotin Plus Pucotenlimab in EGFR-High Advanced Cancers

  This phase II study tests whether combining Becotatug Vedotin with Pucotenlimab helps people whose advanced solid tumors express high EGFR.

  Recruiting Phase 2 Tianjin Medical University Second Hospital · Tianjin, Tianjin Municipality · NCT07712029

• Predicting Toripalimab Response in High-Risk Recurrent Renal Cell Carcinoma using MRD

  This study tests whether measuring minimal residual disease after surgery can predict which high-risk RCC patients will benefit from adjuvant Toripalimab.

  Recruiting Tianjin Medical University Second Hospital · Tianjin, Tianjin Municipality · NCT07657325

• Is ongoing systemic immunotherapy needed after achieving tumor-free status in very-high-risk NMIBC?

  This study tests whether patients who have become tumor-free after a systemic immunotherapy-based bladder-sparing treatment can safely stop therapy and instead be watched closely.

  Recruiting at 4 sites Phase 2 Tianjin Medical University Second Hospital · Tianjin and 3 other locations · NCT07625527

• Using urinary tumor DNA to guide how long systemic immunotherapy is given for unresectable very‑high‑risk non‑muscle‑invasive bladder cancer.

  This trial will test whether monitoring urinary tumor DNA lets people with unresectable very‑high‑risk non‑muscle‑invasive bladder cancer stop systemic immunotherapy sooner after they have a complete clinical response.

  Recruiting at 3 sites Phase 2 Tianjin Medical University Second Hospital · Tianjin and 2 other locations · NCT07475403

• Liquid biopsy testing to identify, monitor, and predict recurrence in urothelial carcinoma

  This project tests whether a multi-component liquid biopsy (blood and urine ctDNA, urine tumor DNA, exosomes, and protein biomarkers) can help detect disease, track treatment response, and predict recurrence in people with suspected or confirmed urothelial carcinoma.

  Recruiting Tianjin Medical University Second Hospital · Tianjin · NCT07441499

• Kidney-and-ureter removal with or without template lymph node removal for high-risk upper tract urothelial cancer

  This trial will test whether adding a template lymph node removal to standard kidney-and-ureter surgery helps people with high-risk upper tract urothelial cancer live longer without the cancer coming back.

  Recruiting Tianjin Medical University Second Hospital · Tianjin, Tianjin Municipality · NCT07321210

• Template lymph node surgery plus kidney removal vs kidney removal alone for high-risk kidney cancer

  In people with high-risk kidney cancer, this study tests whether removing a broader set of lymph nodes during kidney removal helps people live longer and have their cancer stay away longer compared with removing only a few affected nodes.

  Recruiting Tianjin Medical University Second Hospital · Tianjin, Tianjin Municipality · NCT07321197

• Nephron-sparing tislelizumab and nab-paclitaxel for renal pelvic cancer

  This study will try combining tislelizumab and nab‑paclitaxel to shrink HER‑2–expressing renal pelvic tumors in adults eligible for ureteroscopic laser ablation.

  Recruiting Phase 2 Tianjin Medical University Second Hospital · Tianjin, Outside U.S. · NCT07233252

• Using urine tumor DNA to guide whether to have a second bladder tumor resection

  This study will test whether a urine tumor DNA (utDNA) test can help decide if adults with T1 or uncertain non‑muscle‑invasive bladder cancer need a second transurethral resection (re‑TURBT).

  Recruiting at 7 sites Tianjin Medical University Second Hospital · Nanchang, Anhui and 6 other locations · NCT07187635

• Sacituzumab tirumotecan plus tagitanlimab for aggressive and neuroendocrine prostate cancer

  This trial tests whether combining sacituzumab tirumotecan with the immunotherapy tagitanlimab helps people with aggressive variant or neuroendocrine prostate cancer that has progressed after newer hormonal treatments.

  Recruiting Phase 2 Tianjin Medical University Second Hospital · Tianjin, Tianjin Municipality · NCT07179783

• Pre-surgery targeted artery embolization plus toripalimab and axitinib for advanced kidney cancer

  This test tries a targeted artery embolization one week before starting toripalimab plus axitinib to shrink advanced kidney tumors and improve outcomes for people preparing for surgery.

  Recruiting Phase 2 Tianjin Medical University Second Hospital · Tianjin, Tianjin Municipality · NCT07172386

• Tunlametinib for NRAS‑mutant non‑melanoma refractory solid tumors

  This trial tests tunlametinib to see if it can shrink or control advanced non‑melanoma solid tumors that have NRAS mutations in patients who have failed standard treatments.

  Recruiting Phase 2 Tianjin Medical University Second Hospital · Tianjin, Tianjin Municipality · NCT07170293

• Using urine tumor DNA/RNA to guide second TURBT in high-risk non-muscle-invasive bladder cancer

  This test tries to see if a urine liquid biopsy measuring tumor DNA and RNA can identify which people with high-risk NMIBC need a second TURBT after initial tumor removal.

  Recruiting at 2 sites Tianjin Medical University Second Hospital · Tianjin and 1 other locations · NCT07130578

• Neoadjuvant tislelizumab plus nab‑paclitaxel before radical nephroureterectomy for upper tract urothelial carcinoma

  This will test whether giving the PD‑1 drug tislelizumab together with nab‑paclitaxel before surgery helps people with non‑metastatic upper tract urothelial carcinoma.

  Recruiting Phase 2 Tianjin Medical University Second Hospital · Tianjin, Outside U.S. · NCT07126119

• Neoadjuvant tislelizumab plus nab‑paclitaxel before kidney‑sparing distal ureterectomy for ureteral cancer

  This will try giving people with non‑metastatic ureteral cancer two to three cycles of tislelizumab plus nab‑paclitaxel before a kidney‑sparing distal ureterectomy to see if tumor response improves and the treatment is tolerable.

  Recruiting Phase 2 Tianjin Medical University Second Hospital · Tianjin, Outside U.S. · NCT07125547

• Combining Pazopanib and Palbociclib for Hard-to-Treat Solid Tumors

  This study is testing a new combination of two drugs, Pazopanib and Palbociclib, to see if it can help people with hard-to-treat solid tumors that have certain genetic changes.

  Recruiting Phase 1/2 Tianjin Medical University Second Hospital · Tianjin, Tianjin Municipality · NCT06895733

• Precision medicine for patients with advanced solid tumors who have exhausted standard treatments

  This study is testing personalized treatment plans based on genetic differences to see if they can help people with advanced solid tumors who haven't had success with standard treatments.

  Recruiting Phase 2 Tianjin Medical University Second Hospital · Tianjin, Tianjin Municipality · NCT06739395

• Treatment for advanced prostate cancer with CDK12 mutations

  This study is testing a new treatment called vediximab, alone or with another drug, to see if it helps men with advanced prostate cancer that has specific genetic changes and hasn’t responded to other therapies.

  Recruiting Phase 1/2 Tianjin Medical University Second Hospital · Tianjin, Tianjin Municipality · NCT06663007

• Using Tislelizumab and Disitamab-vedotin for Neoadjuvant Therapy in High-risk Upper Tract Urothelial Carcinoma

  This study is testing a new combination of two drugs, tislelizumab and disitamab-vedotin, to see if they can safely help people with high-risk upper tract urothelial carcinoma before surgery, especially for those who can't take traditional chemotherapy.

  Recruiting Phase 2 Tianjin Medical University Second Hospital · Tianjin · NCT05837806

Quick answers

How many clinical trials run by Tianjin Medical University Second Hospital are recruiting right now?

22, as of November 12, 2026. 2 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 11, Phase 1/2: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →